RLI Corp (NYSE: RLI) CEO receives 22,500-share stock option grant
Rhea-AI Filing Summary
RLI Corp reported that Chief Executive Officer Craig W. Kliethermes received a grant of stock options covering 22,500 shares of common stock at an exercise price of $61.29 per share. The options vest 20% after one year and 20% each year thereafter and expire on August 3, 2034.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kliethermes Craig W
Role
CHIEF EXECUTIVE OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F1 | 22,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option — 22,500 shares (Direct)
Footnotes (1)
- F1. Pursuant to option schedule wherein 20% of the aggregate number of shares granted may be exercised commencing one year from grant date and each year thereafter in 20% increments.
Key Figures
Options Granted: 22,500 options
Exercise Price: $61.29 per share
Underlying Shares: 22,500 shares
+3 more
6 metrics
Options Granted
22,500 options
Stock option grant to CEO Craig W. Kliethermes
Exercise Price
$61.29 per share
Exercise price for the 22,500 granted stock options
Underlying Shares
22,500 shares
Common stock underlying the granted options
Vesting Rate
20% per year
20% exercisable after one year and 20% annually thereafter
First Exercisable Date
August 3, 2027
Date when the first 20% of options may be exercised
Expiration Date
August 3, 2034
Expiration of the granted stock options
Key Terms
Stock Option, underlying security, exercise price, expiration date
4 terms
Stock Option financial
"The reporting person received a grant of Stock Option awards."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
underlying security financial
"Each option relates to an underlying security of common stock."
exercise price financial
"The grant carries an exercise price of $61.29 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The options have an expiration date of August 3, 2034."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did RLI (RLI) disclose for CEO Craig W. Kliethermes?
RLI disclosed that CEO Craig W. Kliethermes received a grant of stock options for 22,500 shares of common stock. These options were awarded at an exercise price of $61.29 per share and are scheduled to vest over several years.
What is the exercise price and term of the new RLI (RLI) stock options?
The granted options have an exercise price of $61.29 per share and an expiration date of August 3, 2034. They become exercisable over time according to the vesting schedule described in the accompanying footnote.
What is the vesting schedule for Craig W. Kliethermes’ RLI (RLI) option grant?
The vesting schedule allows 20% of the 22,500 options to be exercised one year after the grant date, with an additional 20% vesting each year thereafter until all options are fully vested, according to the disclosure footnote.
Are Craig W. Kliethermes’ new RLI (RLI) options tied to a Rule 10b5-1 trading plan?
The disclosure indicates the Rule 10b5-1 checkbox is not marked, meaning this reported grant is not designated as made under a Rule 10b5-1 trading plan. It is reported as a standard grant or award acquisition.